Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inotersen in Familial Amyloid Polyneuropathy (NEURO-TTR)
NCT01737398Phase 3Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- Mar 2013
- Primary completion
- Mar 2017
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 10
01
Overview
A Phase 3 trial of inotersen in familial amyloid polyneuropathy (FAP), sponsored by Ionis Pharmaceuticals. Started Mar 2013; status: completed.
02
Drugs
inotersen
03
Conditions
familial amyloid polyneuropathy (FAP)
Beyond the preview
Go deeper on NCT01737398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01737398.